FibroGen’s (FGEN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of FibroGen (NASDAQ:FGEN) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com assumed coverage on shares of FibroGen in a research report on Thursday, February 13th. They set a “hold” rating for the company.

FibroGen Trading Down 8.6 %

Shares of FibroGen stock opened at $0.71 on Thursday. The business’s fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.43. The firm has a market capitalization of $71.13 million, a P/E ratio of -0.57 and a beta of 0.75. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.80.

Hedge Funds Weigh In On FibroGen

Institutional investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp lifted its holdings in FibroGen by 416.6% during the fourth quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 441,083 shares during the last quarter. Velan Capital Investment Management LP purchased a new stake in FibroGen during the fourth quarter valued at about $42,000. Squarepoint Ops LLC purchased a new stake in FibroGen during the fourth quarter valued at about $205,000. Two Sigma Investments LP lifted its holdings in FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 98,888 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 135,600 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.